Journal of Computer-Aided Molecular Design

, Volume 25, Issue 7, pp 607–610 | Cite as

Fragment-based lead discovery: challenges and opportunities

  • Chaohong Sun
  • Andrew M. Petros
  • Philip J. Hajduk
Article

Abstract

Fragment-based lead discovery has undergone remarkable changes over the last 15 years. During this time, the pharmaceutical industry has changed dramatically as well, and continued evolution of the industry is assured. These changes present many challenges but also several opportunities for executing fragment-based drug design. This article will explore some of the more significant changes in the industry and how they may affect future discovery efforts related to fragment-based initiatives.

Keywords

Fragment-based drug design Biologics Off-shoring Outsourcing 

References

  1. 1.
    Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Science 274:1531–1534CrossRefGoogle Scholar
  2. 2.
    de Kloe GE, Bailey D, Leurs R, de Esch IJ (2009) Drug Discov Today 14:630–646CrossRefGoogle Scholar
  3. 3.
    Congreve M, Chessari G, Tisi D, Woodhead AJ (2008) J Med Chem 51:3661–3680CrossRefGoogle Scholar
  4. 4.
    Siegal G, Ab E, Schultz J (2007) Drug Discov Today 12:1032–1039CrossRefGoogle Scholar
  5. 5.
    Albert JS, Blomberg N, Breeze AL, Brown AJ, Burrows JN, Edwards PD, Folmer RH, Geschwindner S, Griffen EJ, Kenny PW, Nowak T, Olsson LL, Sanganee H, Shapiro AB (2007) Curr Top Med Chem 7:1600–1629CrossRefGoogle Scholar
  6. 6.
    Erlanson DA (2006) Curr Opin Biotechnol 17:643–652CrossRefGoogle Scholar
  7. 7.
    Hajduk PJ (2006) Nat Chem Biol 2:658–659CrossRefGoogle Scholar
  8. 8.
    Hajduk PJ (2006) J Med Chem 49:6972–6976CrossRefGoogle Scholar
  9. 9.
    Rees DC, Congreve M, Murray CW, Carr R (2004) Nat Rev Drug Discov 3:660–672CrossRefGoogle Scholar
  10. 10.
    Hajduk PJ, Greer J (2007) Nat Rev Drug Discov 6:211–219CrossRefGoogle Scholar
  11. 11.
    Chessari G, Woodhead AJ (2009) Drug Discov Today 14:668–675CrossRefGoogle Scholar
  12. 12.
    Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) Nat Rev Drug Discov 9:203–214Google Scholar
  13. 13.
    Projan SJ (2003) Curr Opin Microbiol 6:427–430CrossRefGoogle Scholar
  14. 14.
    Sams-Dodd F (2005) Drug Discov Today 10:1049–1056CrossRefGoogle Scholar
  15. 15.
    Sams-Dodd F (2005) Drug Discov Today 10:139–147CrossRefGoogle Scholar
  16. 16.
    Hall SE (2006) Drug Discov Today 11:495–502CrossRefGoogle Scholar
  17. 17.
    Schadt EE, Friend SH, Shaywitz DA (2009) Nat Rev Drug Discov 8:286–295CrossRefGoogle Scholar
  18. 18.
    van der Greef J, McBurney RN (2005) Nat Rev Drug Discov 4:961–967CrossRefGoogle Scholar
  19. 19.
    Congreve M, Marshall F (2010) Br J Pharmacol 159:986–996CrossRefGoogle Scholar
  20. 20.
    Hubbard RE (2010) Neuropharmacology 60:7–23CrossRefGoogle Scholar
  21. 21.
    Congreve M, Rich RL, Myszka DG, Figaroa F, Siegal G, Marshall FH (2011) Methods Enzymol 493:115–136CrossRefGoogle Scholar
  22. 22.
    Goodman M (2009) Nat Rev Drug Discov 8:837CrossRefGoogle Scholar
  23. 23.
    Wong NS, Kocher HP, Yap MG (2007) Biotechnol J 2:657–658CrossRefGoogle Scholar
  24. 24.
    Huth JR, Park C, Petros AM, Kunzer AR, Wendt MD, Wang X, Lynch CL, Mack JC, Swift KM, Judge RA, Chen J, Richardson PL, Jin S, Tahir SK, Matayoshi ED, Dorwin SA, Ladror US, Severin JM, Walter KA, Bartley DM, Fesik SW, Elmore SW, Hajduk PJ (2007) Chem Biol Drug Des 70:1–12CrossRefGoogle Scholar
  25. 25.
    Hung AW, Silvestre HL, Wen S, Ciulli A, Blundell TL, Abell C (2009) Angew Chem Int Ed Engl 48:8452–8456CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Chaohong Sun
    • 1
  • Andrew M. Petros
    • 1
  • Philip J. Hajduk
    • 1
  1. 1.Pharmaceutical Discovery DivisionAbbott LaboratoriesAbbott ParkUSA

Personalised recommendations